We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+12.14%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$118M
AUM Growth
+$622K
Cap. Flow
-$2.07M
Cap. Flow %
-1.75%
Top 10 Hldgs %
96.19%
Holding
19
New
–
Increased
2
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
ALDX icon
Aldeyra Therapeutics
ALDX
+$2.92M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$803K

Top Sells

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$5.71M
2
VNRX icon
VolitionRx Ltd
VNRX
+$61.9K
3
ADXSW
Advaxis Inc Warrants
ADXSW
+$20K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
1
Corbus Pharmaceuticals
CRBP
$170M
$30.5M 25.76%
135,426
+4,964
+4% +$803K
ABEO icon
2
Abeona Therapeutics
ABEO
$345M
$29.6M 25.05%
94,391
– –
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$27.9M 23.6%
749,815
– –
ALDX icon
4
Aldeyra Therapeutics
ALDX
$91.7M
$6.32M 5.34%
484,096
+360,000
+290% +$2.92M
ECOR icon
5
electroCore
ECOR
$51.4M
$5.67M 4.79%
26,481
– –
KRYS icon
6
Krystal Biotech
KRYS
$9.88B
$5.1M 4.31%
300,000
– –
GLMD icon
7
Galmed Pharmaceuticals
GLMD
$3.94M
$2.88M 2.44%
1,167
– –
ENTX icon
8
Entera Bio
ENTX
$101M
$2.41M 2.03%
475,540
– –
AVXL icon
9
Anavex Life Sciences
AVXL
$222M
$1.87M 1.58%
724,205
– –
SNGX icon
10
Soligenix
SNGX
$5.5M
$1.52M 1.29%
3,494
– –
NTBL
11
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$1.49M 1.26%
25,622
– –
VNRX icon
12
VolitionRx Ltd
VNRX
$12M
$916K 0.77%
16,071
-1,506
-9% -$61.9K
EIGR
13
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$910K 0.77%
2,508
– –
EVOK
14
DELISTED
Evoke Pharma
EVOK
$825K 0.7%
1,910
– –
NAGE
15
Niagen Bioscience
NAGE
$256M
$192K 0.16%
47,866
– –
OTRK
16
DELISTED
Ontrak
OTRK
$102K 0.09%
101
– –
LPCN icon
17
Lipocine
LPCN
$17.1M
$69K 0.06%
2,941
– –
AMPE
18
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
– –
-8,652
Closed -$5.71M
ADXSW
19
DELISTED
Advaxis Inc Warrants
ADXSW
– –
-112,500
Closed -$20K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Knoll Capital Management held 19 positions worth $118M, up 0.53% from $118M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Knoll Capital Management's Q3 2018 filing shows 2 increased, 1 reduced and 2 closed positions. The largest sale was Ampio Pharmaceuticals Inc., an estimated $5.71M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Knoll Capital Management added most to Aldeyra Therapeutics in Q3 2018, an estimated $2.92M increase.
  • Knoll Capital Management's biggest Q3 2018 reduction was VolitionRx Ltd, cutting an estimated $61.9K.
  • Knoll Capital Management fully exited Ampio Pharmaceuticals Inc. in Q3 2018, selling an estimated $5.71M.
  • Knoll Capital Management's ten largest holdings make up 96% of its $118M portfolio in Q3 2018.
  • Knoll Capital Management opened 0 new positions and closed 2 in Q3 2018.
  • Knoll Capital Management's portfolio value rose 0.53% quarter-over-quarter to $118M.

Based on Knoll Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.